Related Experiment Video
Updated: May 26, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Clinically significant drug interactions with newer antidepressants
Edoardo Spina1, Gianluca Trifirò, Filippo Caraci
1Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy. espina@unime.it
CNS Drugs
|December 17, 2011
Summary
Newer antidepressants have a lower risk of pharmacodynamic drug interactions but can cause pharmacokinetic interactions, especially duloxetine and bupropion. Understanding these drug interactions is crucial for safe antidepressant prescribing.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Psychiatry
Background:
- Newer antidepressants, beyond selective serotonin reuptake inhibitors (SSRIs), have diverse mechanisms of action.
- Antidepressants are frequently prescribed with other drugs, increasing the likelihood of drug interactions.
- Understanding drug interaction profiles is vital for safe and effective psychiatric treatment.
Purpose of the Study:
- To review the drug interaction profiles of newer antidepressants.
- To compare the interaction potential of newer antidepressants with older classes like MAOIs and TCAs.
- To identify newer antidepressants with potentially significant drug interaction risks.
Main Methods:
- Review of literature on the pharmacokinetics and pharmacodynamics of newer antidepressants.
- Analysis of cytochrome P450 (CYP) enzyme interactions.
- Assessment of clinical significance of potential drug interactions.
Main Results:
- Newer antidepressants generally have lower pharmacodynamic interaction risks compared to MAOIs and TCAs.
- Pharmacokinetic interactions are more common, primarily due to hepatic metabolism via CYP enzymes.
- Duloxetine and bupropion are moderate inhibitors of CYP2D6, posing a risk with narrow therapeutic index drugs.
- Most other newer antidepressants have minimal impact on CYP enzymes.
Conclusions:
- While generally safer, newer antidepressants can cause clinically relevant drug interactions, particularly pharmacokinetic ones.
- Clinicians should be aware of the specific interaction profiles of antidepressants.
- Selecting antidepressants with favorable interaction profiles can enhance patient safety.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...